|
|
 |
A Novel High-Throughput Cell-Based ELISA Assay for Screening of Anti-Inflammatory Drugs |
|
Poster: Rudolf Lucas, Christoph Wiesner, Maren Pflueger, Barbara Entler, Rainer Fedra, Richard Oseghale, Lore Koller, Josef Atzler, Wolfgang Schütt, Christoph Kleber and Harald Hundsberger:
Inflammation is a complex process involving interactions between different cell types and is partially mediated by adhesion molecules. Lung microvascular endothelial cells (L-MVEC) represent major target cells in diseases associated with lung inflammation, such as Adult Respiratory Distress Syndrome (ARDS). Therefore, the search for novel anti-inflammatory factors acting on these cells is therapeutically promising. |
|
 |
PARADIGM™ Detection Platform |
To this purpose, we have developed a novel, high-throughput screening assay making use of the PARADIGM™ Detection Platform from Beckman Coulter, for the identification of antiinflammatory
substances acting on human L-MVEC.
Click here for this poster (PDF)
Additional Information:
|
* All trademarks are the property of their respective owners. Where applicable,
the PCR process is covered by patents owned by Roche Molecular Systems, Inc.,
and F. Hoffmann-LaRoche, Ltd.
For Research Use Only; not for use in diagnostic procedures.
For comments or questions about T3 Update, please contact the T3 Editor.
Email this page to a colleague
|
